English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Select site language

Ibandronic acid Accord (ibandronic acid) – Conditions or restrictions regarding supply and use - M05BA06

Updated on site: 07-Oct-2017

Medication nameIbandronic acid Accord
ATC CodeM05BA06
Substanceibandronic acid
ManufacturerAccord Healthcare Ltd

A.MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Accord Healthcare Ltd. Sage House

319 Pinner road

North Harrow, Middlesex HA1 4HF United Kingdom

The printed package leaflet of the medicinal product must state the name and address of the Manufacturer responsible for the release of the concerned batch.

B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Ibandronic acid Accord 2 mg and 6 mg concentrate for solution for infusion (for oncology indications):

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

Ibandronic acid Accord 3 mg solutionfor injection (for osteoporosos indications): Medicinal product subject to medical prescription.

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

Additional risk minimisation measures

The MAH shall ensure that a patient reminder card regarding osteonecrosis of the jaw is implemented.

Comments

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed